Deals channel feed – Endpoints News

Deals channel feed

Joining a global M&A spree, Astellas reserves $2B for a spate of new biotech acquisitions

8 years ago

Flush with a $164M raise, Cellectis ups its bet on CAR-T and gene editing programs

8 years ago

Biotech M&A is ripping along now as IPOs surge and venture cash flows. Who's the next big target?

8 years ago

Alexion takes its first step rebuilding the pipeline, adding a rare disease drug in $855M cash buyout

8 years ago

Novartis CEO Vas Narasimhan cuts loose an old anchor and sets sail with $8.7B AveXis buyout

8 years ago

With a deadline looming, Takeda CEO Weber woos analysts for support of a Shire buyout

8 years ago

Ferring buys up PhIII microbiome drug with acquisition of Rebiotix

8 years ago

Eyeing growth in regenerative medicine, Fujifilm spends $800M on two new members of its CDMO business

8 years ago

Could Takeda pull off a $50B-plus Shire takeover? Maybe, but analysts and investors have their doubts if they should

8 years ago

Shire shares rocket up after Takeda says it's pondering a takeover bid

8 years ago

Novo Nordisk's pick for new chairman signals its ongoing pursuit of M&A deals

8 years ago

Lundbeck bags a PhII Parkinson's drug with $1.1B Prexton buyout deal

8 years ago

The I/O 2.0-combo tech race is on: Merck bags oncolytics player Viralytics in $394M buyout

8 years ago

Roche pays $1.9B for Ex-Googlers’ tech startup Flatiron Health

8 years ago

Charles River bags a rival CRO player in $800M MPI Research buyout

8 years ago

Allergan snatches Australian aesthetics company Elastagen for $95M

8 years ago

Bioverativ execs haul in new fortunes after patiently waiting for Sanofi to bid up its $11.6B exclusive buyout

8 years ago

The Endpoints 100: Biotech execs stampede into 2018 with a cheer for the FDA and bullish feelings on public markets, private investors and a ‘hot’ M&A future

8 years ago

Anatomy of a $9B buyout: Celgene’s quick turn from Juno’s close collaborator to new owner

8 years ago

Hans Bishop gets a $287M payday as Juno execs see windfall fortunes — with a $922M payoff for Arch

8 years ago

Buyout buzz hits fever pitch on report that Nektar is ‘exploring options’

8 years ago

Amgen’s $70B in ‘deal capacity’ post-tax reform puts the spotlight on 'big things' in M&A — analyst

8 years ago

Restless Seattle Genetics snaps up a pivotal-stage cancer drug with $614M Cascadian buyout pact

8 years ago

Sorry Novo: Sanofi wins Ablynx over with $4.8B buyout bid, bagging nanobody platform tech

8 years ago

First page Previous page 108 109 110111112 113 114 Next page Last page